Published in Proc Natl Acad Sci U S A on April 17, 2001
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev (2007) 4.91
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
What has senescence got to do with cancer? Cancer Cell (2005) 2.55
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol (2005) 2.55
INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J (2002) 1.96
Myc proteins as therapeutic targets. Oncogene (2010) 1.88
Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol (2004) 1.85
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Raf-1 regulates Rho signaling and cell migration. J Cell Biol (2005) 1.58
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev (2006) 1.58
Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J (2010) 1.47
ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene (2011) 1.45
C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J (2005) 1.44
p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol (2004) 1.44
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J (2003) 1.44
Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med (2010) 1.43
ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol (2002) 1.39
Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol (2003) 1.38
Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. PLoS One (2014) 1.38
p53 Family and Cellular Stress Responses in Cancer. Front Oncol (2014) 1.33
Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci (2007) 1.30
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis. Oncogene (2011) 1.14
Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol (2002) 1.11
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle (2009) 1.10
ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol Cell Biol (2002) 1.07
Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability. Carcinogenesis (2007) 1.05
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations. Dis Model Mech (2010) 1.04
Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell (2008) 1.03
Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo. J Mol Biol (2008) 1.00
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J (2005) 0.99
p35 is required for CDK5 activation in cellular senescence. J Biol Chem (2010) 0.96
Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J Clin Invest (2012) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res (2011) 0.91
Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest (2013) 0.90
Tgfbeta signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. J Biol Chem (2010) 0.89
AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014) 0.87
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia (2004) 0.85
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. J Biol Chem (2014) 0.82
An allelic series of Trp63 mutations defines TAp63 as a modifier of EEC syndrome. Am J Med Genet A (2013) 0.81
Benzo(a)pyrene-caused increased G1-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts. Toxicol Lett (2008) 0.81
Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer (2010) 0.81
A novel role of RASSF9 in maintaining epidermal homeostasis. PLoS One (2011) 0.80
ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. J Pathol (2012) 0.79
The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. PLoS One (2011) 0.79
ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene (2013) 0.79
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf. PLoS One (2013) 0.77
A distant, cis-acting enhancer drives induction of Arf by Tgfβ in the developing eye. Dev Biol (2013) 0.75
Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 12.39
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell (1994) 9.73
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell (1980) 8.10
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
A matter of life and cell death. Science (1998) 5.33
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
The Pezcoller lecture: cancer cell cycles revisited. Cancer Res (2000) 5.08
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
p19ARF links the tumour suppressor p53 to Ras. Nature (1998) 4.89
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
The ARF/p53 pathway. Curr Opin Genet Dev (2000) 4.13
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (1998) 3.67
Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol (2000) 3.37
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
Tumor spectrum in ARF-deficient mice. Cancer Res (1999) 3.11
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell (1993) 2.62
The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev (1996) 2.61
Stratification and terminal differentiation of cultured epidermal cells. Nature (1982) 2.44
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
Signal transduction from multiple Ras effectors. Curr Opin Genet Dev (1997) 2.16
Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol (2000) 2.02
An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature (1986) 1.86
The cat and mouse games that genes, viruses, and cells play. Cell (1997) 1.85
Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res (1996) 1.65
Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol (2000) 1.41
Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis (1985) 1.36
Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis (2000) 1.19
Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes. J Biol Chem (2000) 1.18
Signal transduction for proliferation and differentiation in keratinocytes. Ann N Y Acad Sci (1988) 1.09
Identification and subcellular distribution of cornified envelope precursor proteins in the transformed human keratinocyte line SV-K14. J Invest Dermatol (1987) 1.05
p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res (2001) 1.01
p53 gene dosage modifies growth and malignant progression of keratinocytes expressing the v-rasHa oncogene. Cancer Res (1994) 0.99
Identification of filaggrin in cultured mouse keratinocytes and its regulation by calcium. J Invest Dermatol (1983) 0.83
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell (1998) 5.92
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (1998) 5.29
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev (1998) 3.92
Comparison of outcome of low-risk labour in an isolated general practice maternity unit and a specialist maternity hospital. J R Coll Gen Pract (1987) 3.63
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 3.32
Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (1999) 2.96
bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A (1997) 2.59
Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med (2000) 2.59
Apoptosis is critical for drug response in vivo. Drug Resist Updat (2001) 2.37
PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev (2000) 2.33
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol (2001) 2.19
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci U S A (1997) 1.62
Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J (1996) 1.61
Clinical implications of p53 mutations. Cell Mol Life Sci (1999) 1.50
Methods for studying pro- and antiapoptotic genes in nonimmortal cells. Methods Cell Biol (2001) 1.46
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene (2012) 1.46
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene (2010) 1.40
Apoptosis and therapy. J Pathol (1999) 1.39
The p53-Bcl-2 connection. Cell Death Differ (2006) 1.39
Outcome of women booked into an isolated general practice maternity unit over eight years. J R Coll Gen Pract (1987) 1.38
Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis (2001) 1.32
p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A (1997) 1.24
p53 modulation of anchorage independent growth and experimental metastasis. Oncogene (1996) 1.23
Granule exocytosis mediates immune surveillance of senescent cells. Oncogene (2012) 1.14
Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev (1997) 1.03
DNA damage responses and chemosensitivity in the E mu-myc mouse lymphoma model. Cold Spring Harb Symp Quant Biol (2000) 1.01
Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A. Leukemia (2011) 0.92
p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene (2007) 0.90
Apaf-1 expression in malignant melanoma. Cell Death Differ (2006) 0.88
Dynamics of the pupil during binocular rivalry. Arch Ophthalmol (1966) 0.87
Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest. Oncogene (2000) 0.85
Transgenic, inducible RNAi in megakaryocytes and platelets in mice. J Thromb Haemost (2010) 0.83
Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ (2000) 0.82
LMP1 of Epstein-Barr virus induces proliferation of primary mouse embryonic fibroblasts and cooperatively transforms the cells with a p16-insensitive CDK4 oncogene. J Virol (2000) 0.79
p53 and p73: seeing double? Nat Genet (2000) 0.79
Progress of the smart bomb cancer virus. Nat Med (1997) 0.78
Primary structure comparison of the proposed low density lipoprotein (LDL) receptor binding domain of human and pig apolipoprotein B: implications for LDL-receptor interactions. J Lipid Res (1988) 0.77
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils. Oncogene (2006) 0.77
Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene (1997) 0.77